Emcure Pharmaceuticals Limited (EPL) has announced the launch of Orofer FCM 750, a new extension of its parenteral iron brand containing Ferric carboxymaltose (FCM).Orofer FCM is a new dosage variant designed to provide a more effective and convenient option for patients with iron deficiency and AIDS.
It is available in 1000mg/ 20ml and 500mg/ 10ml single-use vials, and can be obtained through a prescription from a registered medical practitioner. Indian studies have indicated that most patients need FCM 1500 mg at body weight between 35-70 kgs. A single dose of FCM up to 750 mg of iron can be infused in a short time frame of 15 minutes diluted in 250 ml of normal saline.Anil Kothiyal, President India Business at Emcure Pharmaceuticals said “Orofer FCM will be available in leading pharmacies and hospitals shortly”.
The Intensified National Iron Plus Initiative (I-NIPI) recommended FCM as the first-line treatment for severe and selected cases of mild-to-moderate anemia in pregnant women in India. FCM is a unique iron complex that consists of a ferric hydroxide core stabilized by a carbohydrate shell, enabling controlled iron delivery to target tissues. It can increase serum ferritin and Hemoglobin levels and provide better compliance than oral iron and iron sucrose therapy.
